NSPR InspireMD
- 2.000
- 0.0000.00%
InspireMD News
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today annou
InspireMD Boosts Executive Severance Benefits Ahead of Potential Takeover
InspireMD's (NASDAQ:NSPR) Investors Will Be Pleased With Their Solid 110% Return Over the Last Year
InspireMD to Present Key Trial Results at LINC 2024
InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
Earnings Call Summary | InspireMD(NSPR.US) Q4 2023 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript:Financial Performance:InspireMD reported Q4 revenue increase of 71.6% to $1.76 million, significantly driven by
InspireMD Q4 EPS $(0.16) Beats $(0.20) Estimate, Sales $1.76M Beat $1.63M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 73.33 percent increase over losses of $(0.60) per s
InspireMD 4Q Rev $1.76M >NSPR
InspireMD 4Q Rev $1.76M >NSPR
Press Release: InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. • Foot Locker (NYSE:FL) is likely to report quarterly e
InspireMD Q4 2023 Earnings Preview
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
Management will host a conference call and webcast with the investment community at 8:30 am (EST) that same day to review financial results and provide an update on corporate developments.
Express News | InspireMD Appoints Principal Investigators For Its Upcoming C-GUARDIANS II Clinical Trial Of SwitchGuard Neuroprotection System
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System
TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced
InspireMD Wins CE Mark for Carotid Stent System
InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced
We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4)
InspireMD Reveals Issuance Of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System
InspireMD Reveals Issuance Of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System
Analysis
Price Target
No Data
